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Abstract We report the cloning of the mouse surface GPI-
anchored Ly-6E.l protein from a highly metastatic mouse 
adenocarcinoma cell line CSML-100 by differential display. 
The expression is specific for the metastatic cell line as the 
closely related, non-metastatic mouse adenocarcinoma cell line 
CSML-0 does not express Ly-6E.l. Northern blot analysis 
reveals expression in a number of mouse tumour cell lines, 
exclusively metastatic ones. To date, active Ly-6A/E has only 
been described in lymphoid cells. The correlation between Ly-
6E.1 expression, and the ability to metastasize, is discussed. 
© Federation of European Biochemical Societies. 
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1. Introduction 
The mouse differentiation antigen Ly-6E.l is a member of 
the multigene family Ly-6 and allelic to Ly-6A.2 [1]. The 
family that consists of 8 members is located on chromosome 
15 [2]. Since the cDNA of Ly-6E.l was cloned in 1986, ex-
tensive work has been done to reveal the physiological role of 
this gene. The protein has been shown to be involved in T-cell 
activation and has also been suggested to contribute in cell-
cell adhesion, but no ligand has so far been identified [2-5]. 
To date, functional Ly-6A/E has been restricted to lymphoid 
cells, although its expression in brain, kidney, heart, liver and 
spleen, as well as in polyoma virus-transformed BALB/c 3T3 
cells has been reported [6-9]. 
Ly-6E. 1 is a GPI-anchored protein and thus does not have 
a cytoplasmic domain. Nevertheless, it is well established that 
cross-linking of mAbs against Ly-6A/E can contribute to, or 
even alone induce, activation of T-lymphocytes [2,3,10]. Dif-
ferent models for such a signal transduction through GPI-
anchored proteins have been proposed [10]. The cellular re-
sponses are broad and include increased protein tyrosine 
phosphorylation, raised intracytoplasmic Ca2+ concentration, 
increased IL-2 secretion, elevated N F - K B and AP-1 binding 
activities, as well as a general T-cell stimulation as seen by a 
""Corresponding author. Telefax: (45) 35-25-77-21. 
E-mail: cohn@biobase.dk 
1 Present address: Engelhardt Institute of Molecular Biology, 
32 Vavilov Street, Moscow 117334, Russia. 
Abbreviations: GPI, glycosyl phoshatidyl inositol; RT-PCR, reverse 
transcription-polymerase chain reaction; SDS, sodium dodecyl sul-
phate; PAGE, polyacrylamide gel electrophoresis; bp, base pair(s); 
PMSF, phenylmethylsulfonyl fluoride; DTT, DL-dithiothreitol; rnAb, 
monoclonal antibody; pAb, polyclonal antibody 
prominent increase in incorporation of radiolabelled thymi-
dine [11,12]. However, the function of the Ly-6A/E protein 
in cells other than lymphoid, e.g. epithelial or fibroblast cells, 
has not yet been investigated at the molecular level. 
In the present work, we describe the detection of Ly-6E. 1 
expression in a highly metastatic cell line as well as its expres-
sion pattern in other mouse tumour cell lines. The polymor-
phism of the gene is confirmed (Ly-6AIE), and no rearrange-
ment of the genes appears to determine the expression level. 
The protein is shown to be anchored to the cell surface 
through a GPI moiety. Finally, we discuss the relevance of 
the protein in the metastatic process. 
2. Materials and methods 
2.1. Cell culture 
All cell lines were grown at 37°C, 5% CO2 in Dulbecco's modified 
Eagle's medium (DME) containing 10% fetal bovine serum (Gibco-
BRL, Life Technologies), penicillin (225 IU/ml, kindly provided by 
Leo Pharmaceuticals, Denmark) and streptomycin sulphate (30 ug/ 
ml). 
2.2. Differential display 
Total RNA was isolated by the guanidine thiocyanate method [13] 
and subsequently treated with DNAse 1 (Boehringer-Mannheim). Dif-
ferential display (RT-PCR) was performed as described [14,15] with 
the 3'-primer 5'-TnCG-3' and the 5'-primer 5'-GGTACTAAGG-3' 
(DNA technology, Denmark). Cycling parameters were 94°C for 30 s, 
40°C for 2 min, 72°C for 30 s for 40 cycles followed by 72°C for 7 min. 
2.3. cDNA cloning 
Total RNA from CSML-100 cells was reverse transcribed at 37°C 
for 1 h using the primer 5'-TnCG-3' (DNA technology, Denmark) 
and SuperScript reverse transcriptase (Gibco-BRL). The cDNA was 
PCR amplified using primers complementary to the ultimate 5'- and 
3'-sequences of the Ly-6E.l mRNA (5'-GAATTCCCTG-
CAACCTTGTC-3' and 5'-GGGAGAACAAAGGGTTTATT-3' 
(DNA technology, Denmark)). Cycling parameters were 94°C for 30 
s, 55°C for 2 min, 72°C for 30 s for 25 cycles followed by 72°C for 
7 min. The amplified cDNA was purified through gel electrophoresis, 
and the excised 861 bp fragment was subsequently cloned into pCRlf, 
using the TA Cloning Kit (Invitrogen, USA) as described by the 
manufacturer. 
2.4. Northern hybridisation 
Fifteen micrograms of total RNA from CSML-0 and CSML-100 
cells was electrophoresed on a 1% agarose formaldehyde gel and blot-
ted onto Hybond-N membranes (Amersham, UK). The 861 bp cDNA 
fragment of Ly-6E.l was labelled by random priming using Mega-
prime RPN 1607 (Amersham, UK) with [a-32P]dCTP (3000 Ci/mmol; 
Amersham, UK). The prehybridization and hybridization was carried 
out at 37°C in buffer containing 10 X Denhardt's solution, 4X stand-
ard saline citrate (SSC), 0.4% sodium dodecyl sulfate (SDS), 0.1 mg/ 
ml single-stranded sperm DNA and 50% formamide. Filters were 
washed at 65°C in 0.5 X SSC and 0.2% SDS for 1 h. Autoradiographs 
were done on X-OMAT (Kodak) films for 1-5 days in Hypercassettes 
(Amersham, UK) at —80°C or on Phoshor Screens (Molecular Dy-
namics) and quantitated using a Phosphor Imager (Molecular Dy-
namics). 
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2.5. Southern hybridisation 
Cells were harvested by trypsination and washed in PBS. Chromo-
somal DNA was isolated as described [16] except that a chloroform 
extraction was included and that the DNA was precipitated twice. Ten 
micrograms of DNA was digested for 12 h, electrophoresed in a 0.8% 
agarose gel, and blotted onto Hybond-N membranes (Amersham, 
UK). Hybridisations were performed as described in Section 2.4. 
2.6. DNA sequencing 
Sequencing reactions of plasmid DNA were performed using the 
dideoxynucleotide chain-termination method (Plasmid Sequencing 
Kit, Amersham, USA). The 534 bp Ly-6E.l fragment was sequenced 
using primers 5'-AACAGCTATGACCATG-3', 5'-GTAAAAC-
GACGGCCAGT-3', 5'-CGCCAGTGTGCTGGAATTCG-3' and 
5'-TGATGGATATCTGCAGAATTCGGC-3' (DNA technology, 
Denmark) annealing to pCRII. The 861 bp Ly-6E.l sequence was 
sequenced using the same primers as noted in Section 2.3. 
2.7. Antibodies and peptides 
Polyclonal rat antibodies against Ly-6E.l were obtained by immu-
nization of Vista rats with recombinant Ly-6E.l protein. Peroxidase-
conjugated rabbit anti-rat IgG (P450) and peroxidase-conjugated goat 
anti-rabbit IgG (P448) were purchased from DAKO (Denmark). Rab-
bit polyclonal antibodies against PDGF-R were kindly provided by 
Dr. Klaus Hansen, Danish Cancer Society [17]. 
2.8. Western blotting 
Cells were lysed in TNT buffer (1% Triton X-100, 150 mM NaCl, 
50 mM Tris-HCl (pH 8.0), 25 mM NaF, 1 mM Na3V04 , 1 mM DTT, 
200 ug/ml PMSF and 2 |Xg/ml each of aprotinin, leupeptin and anti-
pain), and protein concentrations were determined using the Bradford 
assay (Bio-Rad). Samples were subjected to SDS-PAGE as described 
[16]. After electrophoresis, proteins were transferred to Hybond-C 
nitrocellulose filters (Amersham) using a semidry blotting system. 
After blocking the filter for 1 h in blocking buffer (20 mM Tris-
HCl, 150 mM NaCl, 0.05% Tween 20, 5% non-fat dry milk powder), 
filters were incubated with primary antibody (anti-Ly-6E. 1 pAb, 
1:1000; anti-PDGF-R pAb, 1:400) in blocking buffer for 1 h at 
room temperature or at 4°C overnight. Incubation with secondary 
antibodies were done in blocking buffer for 1 h at room temperature. 
An enhanced chemiluminescence detection system (ECL, Amersham) 
was used for developing filters. 
2.9. PI-PLC treatment of cells 
Cells were detached using PBS (without Ca2+ and Mg2+, supple-
mented with 2.5 mM EDTA) and washed in PBS. The cells were 
incubated in DME with or without 40 ug/ml PI-PLC at 37°C for 
1.5 h. Cells were washed and lysed as described in Section 2.8. E. 
coll containing the pIC plasmid encoding B. cereus PI-PLC was kindly 
proveded by Dr. Dirk Heinz, University of Freiburg, Germany. Pu-
rification of PI-PLC was performed as described [18]. 
3. Results 
3.1. Detection, cloning and expression 
Differential display was performed on total R N A from the 
two cell lines, CSML-0 and CSML-100. This resulted in a 
number of amplified sequences of which one was 534 bp, 
Fig. 1. Expression of Ly-6E.l mRNA and protein in CSML-100 and CSML-0 cells. A: Northern blot analysis of total RNA (15 ug/lane). The 
filter was hybridized with the 861 bp of Ly-6E.l cDNA (a), stripped and reprobed with ß-actin (b). Lane 1: CSML-100; lane 2: CSML-0. 
B: Western blot analysis of total cell lysate from CSML-100 (lane 1) and CSML-0 cells (lane 2) using rat polyclonalclonal antibodies against 
Ly-6E.l. 
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which was only detectable in CSML-100 cells. The fragment 
was cloned and sequenced and shown to be the 534 3' bp of 
Ly-6E.l mRNA. 
To perform further investigation of this differential Ly-6E. 1 
expression, the full-length sequence of Ly-6E.l mRNA was 
cloned from CSML-100 cells by RT-PCR. The cloned se-
quence was 861 bp, and thus did not contain the described 
15 bp intron-like sequence from bp 61 to 75 [1]. 
To reveal the exact level of expression in the metastatic and 
the non-metastatic cell lines, Northern blot analysis was per-
formed. It was shown that the mRNA level in CSML-100 cells 
was relatively high (Fig. 1A, lane 1), whereas no expression 
was detected in CSML-0 cells (Fig. 1A, lane 2). 
The cell line-specific Ly-6E. 1 expression was also confirmed 
at the protein level, as determined by Western blot analysis 
using generated polyclonal antibodies (Fig. IB). As expected, 
a high level of protein expression was seen in CSML-100 cells 
(lane 1) while no protein was observed in CSML-0 cells (lane 
2). The protein appeared as a doublet, with sizes between 14 
and 15 kDa, which is in good correlation with earlier data 
from lymphoid cells. The different mobility of the two Ly-
6E. 1 forms has been explained by different states of glycosy-
lation [19]. 
To localize the Ly-6E.l protein in cells, immunocytostain-
ing was performed. These experiments showed that Ly-6E. 1 is 
expressed mainly on the cell surface of CSML-100 cells (data 
not shown). No staining was seen on CSML-0 cells. 
Fig. 2. Sensitivity of the Ly-6E.l protein to PI-PLC in CSML-100 
cells, a: Cells were treated with PI-PLC for 1.5 h as described in 
Section 2.9. Cell lysates from treated (+) or untreated (—) cells were 
subjected to Western blot analysis, using rat anti-Ly-6E.l pAb. b: 
Western blot analysis using rabbit anti-PDGF-R of the same cell ly-
sates as in (a), as a control for unspeciflc protease activity in the 
PI-PLC purification. 
3.2. Ly-6E.l is anchored to the membrane via a GPI-anchor on 
CSML-100 cells 
Ly-6E.l is described to be GPI-anchored on the cell mem-
brane of lympoid cells. Knowing that the protein is expressed 
on the cell surface, and that it exists in two forms (Fig. IB), 
lead us to investigate the nature of the two variants of the 
protein. To clarify whether both of the two forms are located 
on the cell surface, and whether they are both GPI-anchored, 
Fig. 3. Expression of Ly-6A/E mRNA in different mouse tumour cell lines and a fibroblast cell line. Northern blot analysis of total RNA (15 
ug/lane). The names of the used cell lines is indicated over each lane. The loading is balanced according to ethidium bromide staining of the 
agarose gel. The Ly-6E.l probe used is cross-hybridizing with the allelic Ly-6A.2 mRNA. The metastatic ability was determined through subcu-
taneous injection. 
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treatment of whole cells with a GPI-specific phospholipase C 
(PI-PLC) was performed. CSML-100 cells were treated with 
purified recombinant B. cereus PI-PLC (see Section 2.9), and 
total cell lysate were subjected to Western blot analysis. Upon 
PI-PLC treatment, both protein bands almost disappeared 
(Fig. 2a), showing that they both represent GPI-anchored 
forms of the protein. To exlude that the removal of Ly-6E. 1 
is caused by contaminating protease activity in the PI-PLC 
preparation, Western blot against the PDGF receptor from 
the same lysates was performed. The transmembrane receptor 
protein remained intact after the treatment (Fig. 2b), verifying 
the purity of the PI-PLC. 
Thus, Ly-6E.l is GPI-anchored on the cell membrane of 
CSML-100 adenocarcinoma cells, as on lymphoid cells. 
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Fig. 5. Homology between the proteins Ly-6E.l, mouse uPAR and 
mouse EGFR. It is visible that there is high homology in the signal 
sequence of all proteins. All of the 10 cysteines in the mature Ly-
6E.1 protein that are important for forming structural important in-
trachain disulflde bonds are conserved in uPAR and EGFR. - indi-
cates the amino acid to which the GPI-anchor is attached on Ly-
6E.1 and uPAR. *Only the sequence N-terminal of amino acid num-
ber 79 in Ly-6E.l (or homologous sequences in muPARl and 
mEGFR) onto which the GPI-moiety is attached are shown. 
3.3. Ly-6AIE mRNA expression in various mouse tumour cell 
lines 
To investigate whether Ly-6A/E is commonly expressed in 
mouse tumour cell lines, Northern blot analysis of a number 
of cell lines was performed. Eight cell lines, in addition to 
CSML-0 and CSML-100, were selected. All cell lines are 
mouse adenocarcinomas, except Line 1 and LL Met which 
are lung carcinomas. Of the 10 cell lines, Ly-6A7E was exclu-
sively expressed in metastatic ones (Fig. 3). Expression was 
also detected in 10T1/2, which is an immortalized fibroblast 
cell line. 
Thus, Ly-6A/E seems to be overrepresented in metastatic 
cell lines versus non-metastatic ones. 
Fig. 4. Southern blot analysis of .EcoRI-digested chromosomal 
DNA from various mouse and human tumour cell lines and a 
mouse fibroblast cell line. The 861 bp Ly-6E.l cDNA was used as 
radioactive probe. Approximately 10 |ig DNA are loaded in each 
lane. The cell lines used are indicated over each lane. Molecular 
sizes (in kb) are indicated at the left side. Arrows in (A) indicate 
Ly-6E.l-specific bands whereas arrows in (B) indicate Ly-6A.2-spe-
cific bands. 
3.4. Southern blot analysis excludes genomic rearrangement or 
gene duplication of Ly-6AIE 
To study the origin of this cell-specific expression, Southern 
blot analysis of the Ly-6AIE gene, in CSML-0 and CSML-100 
cells, as well as in other tumor cell lines, was performed. Ly-
6E.1 cDNA was used as radioactive probe, knowing that it 
cross-reacts with the sequences of other members of the Ly-6 
gene family. In Fig. 4, a Southern blot of ücoRI-digested 
DNA from 11 cell lines is shown. The restriction pattern for 
CSML-0 and CSML-100 seems to be identical. There also 
seems to be no major differences in the banding pattern 
among the other Ly-6a haplotype (Ly-6E.l) cell lines, irrespec-
tive of Ly-6E.l expression (all Ly-6a cell lines originate from 
either A/Sn or BALB/c mice). Two cell lines, LL Met and 
NIH 3T3 (originating from C57BL/6 and Swiss mice, respec-
tively), were shown to be of the Ly-6b haplotype (Ly-6A.2 
allele), both expressing the gene. The intensity of the Ly-6A7 
E-specific bands is well correlated with the amount of DNA in 
each lane, as determined by ethidium bromide staining of the 
agarose gel before blotting (data not shown). It is therefore 
unlikely that substantial rearrangement of the Ly-6 Al E gene, 
as well as gene duplication, is causing the differential expres-
sion. More likely, is a specific transcriptional regulation of the 
Ly-6A/E gene in the investigated tumor cell lines. 
4. Discussion 
In the presented experiments, the Ly-6E.l gene is identified 
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as highly expressed in a highly metastatic mouse adenocarci-
noma cell line, CSML-100. In contrast, the gene is not ex-
pressed in a non-metastatic mouse adenocarcinoma cell line, 
CSML-0. 
In order to get a picture of the Ly-6A/E expression in 
mouse tumor cell lines in general, eight additional cell lines 
were checked. Five cell lines expressed Ly-6A/E at various 
levels. All of these cell lines are metastatic, no expression 
was seen in non-metastatic ones. 
The described expression pattern in different mouse tumor 
cell lines, motivates speculation of this genes involvement in 
tumorigenesis and tumor progression. However, the cell lines 
10T1/2 (from C3H mice) and NIH 3T3 (from Swiss mice), 
which both are immortalized fibroblasts, does express Ly-
6E.1 and Ly-6A.2, respectively, at high levels (Fig. 3, data 
not shown). Both of these cell lines are non-transformed 
and thus non-tumorigenic. This shows that Ly-6A/E not per 
se is a transforming protein, oncogene, but that its expression 
in metastatic cell lines might contribute to the progression 
towards a more aggressive phenotype. The data are in good 
agreement with the recent report, in wich the malignant phe-
notype of Ly-6A/E-expressing polyoma virus-transformed 
BALB/c 3T3 cells, was described [5]. The cells were trans-
formed, and sorted in populations expressing Ly-6A/E at 
high versus low levels. In vivo experiments showed that the 
population expressing Ly-6A/E at a high level simultaneously 
displayed a considerably more malignant phenotype. The 
question whether the Ly-6E.l expression itself is persuading 
the increased metastatic ability, or if it simply is a sign and a 
secondary effect of increased malignancy, has not yet been 
answered. 
The involvement of Ly-6A/E in tumor progression can with 
the present data be hypothesized in two ways. 
First, is its ability to mediate signal transduction in T-cells a 
possible explanation. It has earlier been shown that cross-link-
ing of Ly-6E.l can mediate increased binding activities of 
nuclear factor KB (p65-p50) and AP-1 (Fos/Jun) [11]. The 
increased activity of these transcription factors may promote 
the tumour progression. Nonetheless, it should be noted that 
since no ligand for Ly-6E.l has been identified, all results 
obtained through cross-linking experiments using mAbs 
against this protein may be irrelevant. 
A second theory is based on the fact that Ly-6A/E can 
confer homotypic aggregation of transgenic thymocytes over-
expressing Ly-6A/E as well as aggregation with non-transgen-
ic thymocytes, T-lymphocytes and B-lymphocytes [5]. This 
shows that Ly-6A/E is involved in cell-cell adhesion and 
that there exists a naturally occurring ligand expressed on at 
least lymphoid cells. The data are obtained by in vitro experi-
ments; thus it is still unknown whether the shown adhesion 
has a physiological role. Nevertheless, it is not difficult to 
speculate a possible role in metastasis. Metastasis is a multi-
step cascade where adhesion of the tumor cells to endothelial 
cells in the distant organ is a crucial step [20]. The proposed 
involvement of Ly-6A/E in this process has to be investigated 
closer. 
When interpreting the above considerations, one should 
know that the Ly-6E. 1 protein has high homology with struc-
tural important amino acids in both uPAR and mouse EGFR. 
The scheme in Fig. 5 shows that in addition to homology in 
the signal sequence, all 10 cysteines in the mature Ly-6E.l 
protein can be aligned to the two other proteins. This suggests 
a related tertiary structure of the proteins and can indicate a 
similar or related function among them. This might help in 
the study of the function of Ly-6E.l in cancer cells, as well as 
in the search for a ligand. Recently two human genes, E48 [21] 
and RIG-E [22], were cloned. Both proteins have high homol-
ogy to members of the Ly-6 family. This might indicate the 
presence of a human 'Ly-6' gene family. 
To investigate the speculated roles and importance of Ly-
6E.1 in the metastatic cascade, transfection experiments con-
ducting gain and loss of function of this protein, involving 
different tumour cell lines, followed by in vivo investigations 
need to be done. 
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